- CEO
- David A. Johns
- Full Time Employees
- 2,841
- Sector
- Process industries
- Industry
- Containers/Packaging
- Address
- 100 Saulteaux Crescent Winnipeg MB Canada R3J 3T3
- IPO Date
- Aug 28, 1986
- Business
- Winpak Ltd. manufactures and distributes high-quality packaging materials and related packaging machines primarily for the protection of perishable foods, beverages, dairy products, pharmaceuticals, medical devices, and personal care items; the company operates through three main segments including flexible packaging with modified atmosphere packaging for meats, poultry, and cheese, specialty films for printing and laminating, and biaxially oriented nylon films; rigid packaging and flexible lidding encompassing rigid containers such as portion control trays, custom retort trays, and plastic sheets alongside lidding in die-cut, daisy chain, and rollstock formats plus specialized printed packaging for healthcare and nutraceuticals; and packaging machinery featuring horizontal fill/seal machines for preformed containers and vertical form/fill/seal pouch machines for liquids, semi-liquids, and dry products. Founded in 1975 and headquartered at 100 Saulteaux Crescent in Winnipeg, Manitoba, Canada, Winpak conducts operations across the United States, Canada, Mexico, and other regions, targeting food and beverage processors, pet food manufacturers, dairy producers, and healthcare providers. Recent developments include the substantial expansion of its Winnipeg modified atmosphere packaging facility with capital expenditures projected at $80 to $130 million in 2025 to support 5 to 7 percent sales volume growth in pet food, in-mold-label, dairy, and healthcare markets; approval of near-term science-based emissions reduction targets by the Science Based Targets initiative in September 2025 and publication of its 2025 Sustainability Report; launch of Medform DT forming film for healthcare packaging and promotion of the Winspeed portfolio for pharmaceutical applications; completion of a normal course issuer bid repurchasing over 3 million common shares for approximately US$107 million by early 2025; a special one-time dividend of C$3.00 per share paid in January 2025 alongside a quarterly dividend increase to C$0.05 per share; and ongoing evaluation of strategic acquisitions focused on medical and pharmaceutical opportunities.